The Surgical Ablation segmentation by application delineates four primary use‑cases that collectively drive market revenue. Cardiac arrhythmia ablation—targeting atrial fibrillation, atrial flutter, and ventricular tachycardia—accounts for the largest share, reflecting its entrenched role in electrophysiology and the high procedural volume in developed health‑care systems. Oncology applications, including hepatic, renal, and lung tumor ablation, represent a rapidly expanding niche, propelled by minimally invasive alternatives to resection and growing adoption of image‑guided techniques. Neurology ablation, focused on essential tremor and Parkinson’s disease lesioning, contributes a modest but steady portion, constrained by limited procedural sites and stringent regulatory pathways. Finally, vascular ablation—used for peripheral artery disease and varicose vein treatment—holds the smallest slice, yet benefits from emerging catheter technologies that could elevate its share. Together, these application sub‑segments define the overall market size, with each segment’s growth rate weighted by clinical adoption, reimbursement landscape, and technology diffusion.